...
首页> 外文期刊>Journal of thrombosis and thrombolysis >Construction of thrombus-targeted microbubbles carrying tissue plasminogen activator and their in vitro thrombolysis efficacy: a primary research.
【24h】

Construction of thrombus-targeted microbubbles carrying tissue plasminogen activator and their in vitro thrombolysis efficacy: a primary research.

机译:带有组织纤溶酶原激活物的血栓靶向微泡的构建及其体外溶栓效果:一项初步研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Thrombosis is the common mechanism of various diseases of heart and vasculature and their major morbility and mortality. An efficient, safe and easy thrombolysis method is needed. We tried to develop a new type of ultrasound microbubbles carrying thrombolytics and simultaneously targeting to thrombus, which could bind with thrombus specifically and release the encapsulated drug locally under the ultrasound exposure. Microbubbles carrying tissue plasminogen activator (tPA) and Arg-Gly-Asp-Ser tetrapeptide (RGDS) were prepared by lyopyilization. Their properties were detected, including morphology, particle size, surface potential and pH. The results showed that the microbubbles were suitable for intravenous injection. The envelope rate of tPA, detected by ELISA, was (81.12 +/- 2.44%), and the conjugate rate of RGDS, detected by flow cytometer, was (94.49 +/- 6.19%). The tPA encapsulated in microbubbles kept fibrinolysis activity under the conditions of both natural releasing and ultrasound exposure, checked by agarose fibrin plate process. The contrast-enhanced ultrasonography (CEU) in rabbit liver showed that they were good for enhanced ultrasound imaging. The in vitro thrombolysis of the microbubbles to the blood clots from healthy human was detected with a mimical flowing model propelled by peristaltic pump. The drug-loaded microbubbles plus ultrasound irradiation got higher thrombolysis with the lowest dosage. The tPA-loaded microbubbles targeting to thrombus can be prepared by lyopyilization, which will bring out a novel way for the targeting drug-released thrombolysis therapy.
机译:血栓形成是各种心脏和血管疾病及其主要发病率和死亡率的常见机制。需要一种有效,安全和容易的溶栓方法。我们试图开发一种新型的带有溶栓剂并同时靶向血栓的超声微泡,这种微泡可以与血栓特异性结合,并在超声照射下局部释放封装的药物。通过冻干制备携带组织纤溶酶原激活物(tPA)和Arg-Gly-Asp-Ser四肽(RGDS)的微泡。检测了它们的性质,包括形态,粒度,表面电势和pH。结果表明,微泡适用于静脉内注射。 ELISA检测到的tPA包膜率为(81.12 +/- 2.44%),流式细胞仪检测到的RGDS的结合率为(94.49 +/- 6.19%)。通过琼脂糖纤维蛋白平板法检查,包裹在微泡中的tPA在自然释放和超声暴露的条件下保持纤维蛋白溶解活性。兔肝超声造影(CEU)显示,它们对增强超声成像有好处。用蠕动泵驱动的模拟流动模型检测了微泡对健康人血凝块的体外溶栓。载药微泡加超声辐照以最小的剂量获得更高的溶栓作用。可以通过冻干制备靶向血栓的tPA负载的微泡,这将为靶向药物释放的溶栓治疗提供新的途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号